Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;97(3):e70310.
doi: 10.1002/jmv.70310.

Reflections Regarding Validation of New HPV Tests With Reduced HPV Genotypes: Report From an IARC Expert Consultation

Arianis Tatiana Ramírez  1 , Gary M Clifford  1 , Joakim Dillner  2 , Louise Kuhn  3 , Marc Arbyn  4   5 , Neerja Bhatla  6 , Nicolas Wentzensen  7 , Peter Sasieni  8 , Priya Abraham  9 , Mary Luz Rol  1 , Maribel Almonte  10 , Partha Basu  1
Affiliations

Reflections Regarding Validation of New HPV Tests With Reduced HPV Genotypes: Report From an IARC Expert Consultation

Arianis Tatiana Ramírez et al. J Med Virol. 2025 Mar.

Erratum in

Abstract

Of the 12 HPV genotypes classified as carcinogenic to humans (Group 1), over 95% of HPV-positive cervical cancers are linked to eight genotypes (HPV16/18/31/33/35/45/52/58). Screening programmes may consider HPV tests incorporating only these genotypes to improve screening efficiency and reduce programmatic costs. Validation of such tests requires fine-tuning of existing criteria. An expert group convened by the International Agency for Research on Cancer discussed how existing criteria by Meijer et al. for HPV screening clinical validation should be adapted to evaluate new reduced-valency HPV tests. Experts identified four key criteria: (1) Clinical performance criteria should meet WHO HPV test Target Product Profiles (TPP) minimal standards with high relative sensitivity ( ≥ 0.90 for CIN2+ and ≥ 0.95 for CIN3+) and relative specificity ( ≥ 0.98 for ≤ CIN1) to detect CIN2/3+ lesions associated with types targeted by the test, as established by a comparator test providing information on the presence of the targeted genotypes; (2) Comparator tests should be clinically validated according to Meijer criteria principles for comparator tests, and should offer HPV genotyping to detect at least the types included in the reduced-valency test; (3) Cervical samples should be representative of a population-based screening programme; (4) Intra- and inter-laboratory reproducibility should adhere to Meijer criteria and, preferentially also the more stringent TPP. As the global HPV type distribution in cervical cancer is well known, a future evaluation strategy may consider including both virological and simplified clinical standards. The consultation highlights essential criteria building on existing clinical accuracy standards, enriched with analytical standards. These criteria will be instrumental in ensuring both accuracy and reliability of new reduced-valency HPV tests for cervical cancer screening highly needed to assure 70% coverage aim of cervical cancer elimination.

Keywords: Meijer criteria; WHO HPV test TPPs; cervical cancer; reduced‐valency HPV tests; screening; validation.

PubMed Disclaimer

References

    1. J. M. M. Walboomers, M. V. Jacobs, M. M. Manos, et al., “Human Papillomavirus is a Necessary Cause of Invasive Cervical Cancer Worldwide,” Journal of Pathology 189, no. 1 (September 1999): 12–19, https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431&....
    1. G. Ronco, J. Dillner, K. M. Elfström, et al., “Efficacy of HPV‐Based Screening for Prevention of Invasive Cervical Cancer: Follow‐Up of Four European Randomised Controlled Trials,” Lancet 383, no. 9916 (February 2014): 524–532, https://doi.org/10.1016/S0140-6736(13)62218-7.
    1. A. T. Ramírez, J. Valls, A. Baena, et al., “Performance of Cervical Cytology and HPV Testing for Primary Cervical Cancer Screening in Latin America: An Analysis Within the ESTAMPA Study,” Lancet Regional Health—Americas 26 (October 2023): 100593, https://doi.org/10.1016/j.lana.2023.100593.
    1. R. Sankaranarayanan, B. M. Nene, S. S. Shastri, et al., “HPV Screening for Cervical Cancer in Rural India,” New England Journal of Medicine 360, no. 14 (April 2009): 1385–1394, https://doi.org/10.1056/NEJMoa0808516.
    1. M. Arbyn, G. Ronco, A. Anttila, et al., “Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer,” supplement, Vaccine 30, no. S5 (November 2012): F88–F99, https://doi.org/10.1016/j.vaccine.2012.06.095.

MeSH terms